Abstract: An electronic device, includes: a battery; a microcontroller configured to receive power from the battery along a first path comprising a first battery switch configured to change between an opened configuration and a closed configuration; and a receiver coil configured, in response to being positioned in a changing magnetic field, to generate an alternating electric current and to change, via the alternating electric current, the first battery switch from the opened configuration to the closed configuration.

Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.

Abstract: A stimulation system configured to be implanted in a patient includes an implantable pulse generator (IPG) and an implantable lead system. The IPG includes a processor, a memory device, a power supply, and an inertial sensing unit configured to measure one or more physiological indicators of the patient. The implantable lead system includes at least one electrical lead coupled to the power supply and at least one electrode at a distal end of the electrical lead. The memory device includes instructions that cause the IPG to receive the physiological indicators within an initial range; increase the initial range to an enlarged range in response to the physiological indicators crossing a threshold maximum value or a threshold minimum value of the initial range; receive the physiological signals within the enlarged range, analyze the physiological indicators, and deliver stimulation to the patient through the electrode in response to the physiological indicators.

Abstract: A wireless power transfer system includes a wireless power transfer device configured to determine a magnetic field, from among a plurality of directionally different potential magnetic fields that the wireless power transfer device is configured to generate, that has, at a receiver coil of an electronic device, a direction aligned with the receiver coil.

Abstract: A method for the separation and simultaneous determination of urinary D- and L-lactic acid enantiomers by high performance liquid chromatography tandem mass spectrometry (HPLC/MS/MS). The chiral separation was done using a chirobiotic teicoplanin aglycone column varying mobile phase parameters such as the acetic acid/triethylamine content and the aqueous/organic ratio.

Abstract: A medical system including an implantable battery operated therapy device and an external communication device configured for wireless communication in a manner to minimize energy consumption in the implanted device. The medical device is configured to wake periodically from a sleep state to look for a message preamble from the communication device. The preamble is formatted to include control information, e.g., information indicating the time of receipt of the forthcoming message.

Abstract: A method and apparatus for reallocating in the local memory of an implantable medical device for upgrading operating software stored in the Code portion of the local memory. The local memory is managed so that new software e.g., a code segment, is accepted into memory provisionally, and then validated before being used to replace existing (i.e., old) software. Each new segment is received in its entirety and its integrity validated before the old software is overwritten. Data log information is downloaded to an external programmer at the start of a software upgrade operation to temporarily free memory space without losing any information. This freed memory space is then reassigned for the purpose of temporarily storing new code segments until they can be received in their entirety and validated. A software copying component is transferred from a local memory code portion to a data portion to allow new code segments to be written into any area of said code portion.

Abstract: A drug delivery device which includes a fluid drug reservoir, a catheter, a controllable fluid transfer device, e.g., a pump mechanism or valve, and a drug delivery control means. The drug delivery control means comprises a controller, e.g., a microprocessor or microcontroller which is operable to automatically reduce the rate of drug delivery over a certain reduction interval (e.g., multiple days) from an initial dosage value to a final dosage value.

Abstract: A medical system comprising an implantable medical device and an external controller. The medical device includes a therapy administration subsystem, a telemetry subsystem, and a control subsystem which includes a microprocessor operable in response to data and/or code provided via said telemetry subsystem for producing an output signal for controlling said therapy administration subsystem. The controller includes a user input means and a telemetry subsystem responsive to said user input means for communicating data and/or code to said medical device telemetry subsystem. The medical device control subsystem includes program means for causing said microprocessor to separately execute at least two software processes to respectively produce separate therapy control output components. Combinatorial logic means responds to the separate output components to produce the output signal for controlling the therapy administration subsystem.

Abstract: The present invention relates to an implantable drug delivery device which includes a fluid drug reservoir, a catheter, a controllable fluid transfer device, e.g., a pump or valve, and a drug delivery control means. The control means in accordance with the invention is configured to initially clear a first, or old, drug from the device based on the content of the Current Profile data containing a first, or old, delivery profile. After the old drug is cleared, then the control means automatically modifies the Current Profile data to match a second, or new, delivery profile for controlling delivery of a second, or new, drug.

Abstract: A frequency generation circuit includes an oscillator (403), a comparator (413) coupled to the oscillator, a first divider (407) coupled to the comparator, a PLL (400) coupled to the first divider, a second divider (422) coupled to the PLL, a first multiplexor (409) coupled to the second divider, a third divider (408) coupled to the comparator and the first multiplexor, a second multiplexor (410) coupled to the comparator and the reference clock PLL, a fourth divider (411) coupled to the second multiplexor, a fifth divider (412) coupled to the comparator, and a seventh divider (450) coupled to the comparator. A method of operating a transceiver includes using the frequency generation circuit to provide a first clock signal, a second clock signal, a first reference frequency, and a second reference frequency for a first component, a second component, a third component, and a fourth component, respectively, of the transceiver.